Recombinant human MEK1 (mutated S218 + S222) protein (ab90031)



  • Nature
  • Source
    Escherichia coli
  • Amino Acid Sequence
    • Species


Our Abpromise guarantee covers the use of ab90031 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activity
    Activity: > 250.000 U/mg (1 Unit is defined as the amount of MEK1 which activates unactive ERK1 (0.3 mg/ml) by 1 U/min using 100 µM ATP at 30°C. 1 U ERK1 activity is defined as 1 pmol phosphate transferred to myelin basic protein (0.2 mg/ml) per min using 125 µM ATP at 30°C).
  • Applications


    Functional Studies

  • Purity
    > 90 % SDS-PAGE.
    ab90031 is purified by gluthatione sepharose and gel filtration.
  • Form
  • Additional notes

    MEK1 can be activated by Raf by phosphorylation on serine 218 and serine 222. Mutation of these sites to acidic residues leads to constitutively active MEK1 in some cases.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 50mM Tris HCl, 270mM Sucrose, 150mM Sodium chloride, 1mM DTT, 0.1mM EGTA, pH 7.5

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • Dual specificity mitogen activated protein kinase kinase 1
    • Dual specificity mitogen-activated protein kinase kinase 1
    • ERK activator kinase 1
    • MAP kinase kinase 1
    • MAP kinase/Erk kinase 1
    • MAP2K1
    • MAPK/ERK kinase 1
    • MAPKK 1
    • MAPKK1
    • MEK 1
    • Mek1
    • MEKK1
    • Mitogen activated protein kinase kinase 1
    • MKK 1
    • MKK1
    • MP2K1_HUMAN
    • PRKMK1
    • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1)
    • Protein kinase mitogen activated, kinase 1
    see all
  • Function
    Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
  • Tissue specificity
    Widely expressed, with extremely low levels in brain.
  • Involvement in disease
    Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similarities
    Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
    Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt


ab90031 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab90031.
Please use the links above to contact us or submit feedback about this product.


Sign up